Lee Schalop, MD, COO of Oncoceutics to present ONC201 and our clinical trials in glioma patients with the H3 K27M mutation at the BioNJ BioPartnering Conference in Somerset, NJ on May 3, 2018. His presentation will further talk about relevant background information for H3 K27M-mutant brain tumors, including DIPG and other midline gliomas, and discuss
Josh Allen, PhD and SVP of Research and Development at Oncoceutics will be presenting ONC201 at 2018 Experimental Biology in San Diego, April 21 – 25. The presentation will discuss the role of DRD2 in oncology and speak about the ability of imipridones to target GPCRs with a high degree of selectivity. ONC201, the founding
Oral talk 1 in section ‘GPCR-Targeted Drug Design’ Varun Prabhu: Anti-Leukemic Activity of Imipridone ONC212 via Selective Targeting of Orphan GPCR GPR132/G2A Tuesday, April 3, 2:20 pm | Hilton Bayfront | San Diego, California Oral talk 2 in section ‘Small Molecules for Cancer Immunotherapy’ Josh Allen: The Imipridone ONC201, a Selective DRD2 Antagonist, Exerts Immunostimulatory Activity
ONC201 to be discussed at the Keystone Symposia on Molecular and Cellular Biology on February 20, 2018 Josh Allen of Oncoceutics will be giving a Short Talk under the title of “Differentiated Receptor Pharmacology of Imipridone ONC201: The First DRD2 Antagonist in Clinical Development for Oncology”. The Short Talk is part of the Keystone Symposia
Business Development